There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
The bottom-up assembly of biological and chemical components opens exciting opportunities
to engineer artificial vesicular systems for applications with previously unmet requirements.
The modular combination of scaffolds and functional building blocks enables the engineering
of complex systems with biomimetic or new-to-nature functionalities. Inspired by the
compartmentalized organization of cells and organelles, lipid or polymer vesicles
are widely used as model membrane systems to investigate the translocation of solutes
and the transduction of signals by membrane proteins. The bottom-up assembly and functionalization
of such artificial compartments enables full control over their composition and can
thus provide specifically optimized environments for synthetic biological processes.
This review aims to inspire future endeavors by providing a diverse toolbox of molecular
modules, engineering methodologies, and different approaches to assemble artificial
vesicular systems. Important technical and practical aspects are addressed and selected
applications are presented, highlighting particular achievements and limitations of
the bottom-up approach. Complementing the cutting-edge technological achievements,
fundamental aspects are also discussed to cater to the inherently diverse background
of the target audience, which results from the interdisciplinary nature of synthetic
biology. The engineering of proteins as functional modules and the use of lipids and
block copolymers as scaffold modules for the assembly of functionalized vesicular
systems are explored in detail. Particular emphasis is placed on ensuring the controlled
assembly of these components into increasingly complex vesicular systems. Finally,
all descriptions are presented in the greater context of engineering valuable synthetic
biological systems for applications in biocatalysis, biosensing, bioremediation, or
targeted drug delivery.
Proteins are essential to life, and understanding their structure can facilitate a mechanistic understanding of their function. Through an enormous experimental effort 1 – 4 , the structures of around 100,000 unique proteins have been determined 5 , but this represents a small fraction of the billions of known protein sequences 6 , 7 . Structural coverage is bottlenecked by the months to years of painstaking effort required to determine a single protein structure. Accurate computational approaches are needed to address this gap and to enable large-scale structural bioinformatics. Predicting the three-dimensional structure that a protein will adopt based solely on its amino acid sequence—the structure prediction component of the ‘protein folding problem’ 8 —has been an important open research problem for more than 50 years 9 . Despite recent progress 10 – 14 , existing methods fall far short of atomic accuracy, especially when no homologous structure is available. Here we provide the first computational method that can regularly predict protein structures with atomic accuracy even in cases in which no similar structure is known. We validated an entirely redesigned version of our neural network-based model, AlphaFold, in the challenging 14th Critical Assessment of protein Structure Prediction (CASP14) 15 , demonstrating accuracy competitive with experimental structures in a majority of cases and greatly outperforming other methods. Underpinning the latest version of AlphaFold is a novel machine learning approach that incorporates physical and biological knowledge about protein structure, leveraging multi-sequence alignments, into the design of the deep learning algorithm. AlphaFold predicts protein structures with an accuracy competitive with experimental structures in the majority of cases using a novel deep learning architecture.
Liposomes, sphere-shaped vesicles consisting of one or more phospholipid bilayers, were first described in the mid-60s. Today, they are a very useful reproduction, reagent, and tool in various scientific disciplines, including mathematics and theoretical physics, biophysics, chemistry, colloid science, biochemistry, and biology. Since then, liposomes have made their way to the market. Among several talented new drug delivery systems, liposomes characterize an advanced technology to deliver active molecules to the site of action, and at present, several formulations are in clinical use. Research on liposome technology has progressed from conventional vesicles to ‘second-generation liposomes’, in which long-circulating liposomes are obtained by modulating the lipid composition, size, and charge of the vesicle. Liposomes with modified surfaces have also been developed using several molecules, such as glycolipids or sialic acid. This paper summarizes exclusively scalable techniques and focuses on strengths, respectively, limitations in respect to industrial applicability and regulatory requirements concerning liposomal drug formulations based on FDA and EMEA documents.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.